Targeting actionable mutations, such as epidermal growth factor receptor-mutated and anaplastic lymphoma kinase-gene rearranged in lung cancer, human epidermal growth factor receptor 2-positive breast cancer, and BRAF-mutated melanoma, have led to encouraging results also in leptomeningeal metastases. The gene discussed is ERBB2; the disease is lung cancer.